CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 7 enrolled
Drug / intervention
Human insulincombination
Likely dose
Human insulin 100 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04857320
NCT04857320Early Ph 1Completed
CompareCT.gov

A Physician-Initiated Randomised, Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Transdermal Human Insulin In Adult Healthy Volunteer Patients

Transdermal Delivery Solutions Corp·interventional·Posted Apr 23, 2021·Updated Oct 23, 2023

In Brief

A Early Phase 1 clinical trial evaluating Human insulin for Pharmacodynamic Response to Small Doses of Insulin. Completed, enrolled 7 participants across 1 site.

Detailed Summary

Bio-fermentation produced Human insulin is available without prescription in the U.S. This study is a physician-initiated trial of a formula enabling transdermal delivery of human insulin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacodynamic Response to Small Doses of Insulin
CountriesUnited States
CollaboratorsLangford Research Institute, Inc.

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedApr 23, 2021
Enrollment StartMar 12, 2021
Primary CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.2 years ago

Interventions

Human insulincombination

Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.